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hydrophobic vacuum cleanerABC multidrug transporter proteins expel a wide variety of structurally unrelated, mostly hydrophobic
compounds from cells. The special role of these transporters both at the physiological barriers and in cancer
cells is based on their extremely broad substrate recognition. Since hydrophobic compounds are known to
partition into the lipid bilayer and accumulate in membranes, the “classical pump”model for the mechanism
of multidrug transporter proteins has been challenged, and alternative models suggesting substrate
recognition within the lipid bilayer have been proposed. Although much effort has been made to validate this
concept, unambiguous evidence for direct drug extrusion from the plasma membrane has not been provided
yet. Here we show a detailed on-line microscopic analysis of cellular extrusion of ﬂuorescent anti-cancer
drugs, mitoxantrone and pheophorbide A, by a key human multidrug transporter, ABCG2. Using the fully
active GFP-tagged ABCG2 and exploiting the special character of mitoxantrone that gains ﬂuorescence in the
lipid environment, we were able to determine transporter-modulated drug concentrations separately in the
plasma membrane and the intracellular compartments. Different kinetic models describing the various
transport mechanisms were generated and the experimental data were analyzed using these models. On the
basis of the kinetic analysis, drug extrusion from the cytoplasm can be excluded, thus, our results indicate
that ABCG2 extrudes mitoxantrone directly from the plasma membrane.ette transporter; ABCG2, G2
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Human multidrug transporters, including MDR1, MRP1, and
ABCG2, play crucial role in absorption, distribution, metabolism,
excretion and toxicity of pharmacologically relevant drugs [1–5]. The
medical importance of these transporters is even more evident in
cancer therapy, since they signiﬁcantly contribute to the clinical drug
resistance, hindering the effectivity of chemotherapeutical regimens
[6–10]. Both the physiological and pathophysiological roles of these
transporters are based on their ability to expel an astonishingly wide
variety of drugs from cells. Explaining this extremely broad substrate
recognition remained a major challenge to the scientists for decades,
even though a better understanding of the molecular mechanism ofthese transporters is crucial for the generation of structure-based
speciﬁc drugs and modulators.
Similar to enzymes, most membrane transporter proteins specif-
ically bind one or a limited number of substrates in a well-deﬁned
binding pocket. Following substrate recognition, transporter proteins
translocate the transported substrate from one side to the other side
of the membrane. However, this classical mechanism cannot be
directly applied to the so-called multidrug transporters, which
recognize an exceptionally large number of chemically unrelated
compounds as substrates. In the early 1990s, special transport
mechanisms were proposed to explain the “promiscuity” of these
transporters. Since the transported substrates of the multidrug
transporters are mostly lipophilic, the hypothetical models suggested
less speciﬁc, hydrophobic substrate-transporter interaction within
the lipid bilayer of the membrane. The “hydrophobic vacuum cleaner”
model suggested direct extrusion of the drugs from the membrane
lipid bilayer [11,12], whereas the “ﬂoppase” model proposed
translocation of the substrate from the inner leaﬂet to the outer
leaﬂet of the membrane resulting in a net cellular efﬂux [13].
Although the concept of hydrophobic substrate recognition seems
to be rational, these proposals launched a long-lasting scientiﬁc
debate, since only indirect experimental evidences supported the
alternative models. Some experimental data indicated that ABC
pumps are capable of extruding their substrates before they reach
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membrane-embedded part of the transporter [17–21] and a limited
number of functional studies using reconstituted MDR1/Pgp [17,22,23]
supported the idea of substrate recognition within the membrane.
Recently, we generated and expressed an N-terminally GFP-tagged
version of ABCG2 (GFP-G2), and proved that this fusion protein is fully
functional [24]. The transport activity of GFP-tagged ABCG2 has been
demonstrated in various transport assays using radiolabeled drug
substrate, methotrexate and the ﬂuorescent dye, Hoechst 33342. The
spectral separation in ﬂuorescence techniques allows identifying
subpopulation of cells expressing the transporter, and in parallel,
monitoring cellular dye accumulation. This combined ﬂuorescence
transport assay was proven to be particularly useful in inhomoge-
neous cultures, such as transiently transfected cells [24].
In the present work, we employed the GFP-tagged ABCG2 in
confocal microscopy studies to determine the kinetics of drug
distribution in the plasma membrane and other cellular compart-
ments using the ﬂuorescent anti-cancer agent, mitoxantrone. To
investigate whether ABCG2 acts as a classical pump or extrudes its
transported substrate directly from the plasma membrane, we
generated kinetic models describing the transport processes accord-
ing to both the classical pump model and the alternative models, and
compared the characteristic features of these models with our
experimental observations. We found full agreement between
experimental data and the models, which indicates substrate
recognition by the pump within the plasma membrane.
2. Materials and methods
2.1. Fluorescent drug uptake studies
Cell culturing and expression of GFP-tagged ABCG2 variants in
HEK-293 cells was performed as described in [24]. Brieﬂy, the cells
were maintained in D-MEM containing 10 % FCS, seeded onto eight-
well Lab-Tek II Chambered Coverglass (Thermo Scientiﬁc Nunc) at
5×104 per well cell density. 24 h after seeding the cells were
transfected with GFP-ABCG2 plasmid using the FuGENE® 6 (Roche)
in accordance with the manufacturer's instruction. The medium was
changed 24 h after transfection. Fluorescent drug transport studies
were carried out usually 48 h after transfection, but when cells with
various GFP-G2 expression levels were examined, the cultures were
studied 24 h after transfection.
To study drug uptake kinetics, the transfected cultures were
subjected to 5 μM mitoxantrone (MX) (Sigma-Aldrich) or 2 μm
pheophorbide A (Pheo) (Frontier Scientiﬁc) in serum free culturing
medium (pH 7.4) at room temperature. To block the dye extrusion
activity of the transporter, 1 μM Ko143 (gift of Dr. G.J. Kooman) was
used approximately 5 min after the addition of the drug. The green
(505–525 nm) and far red (N 650 nm) ﬂuorescence were monitored
by an Olympus FV500-IX confocal laser scanning microscope using a
PLAPO 60× (1.4) oil immersion objective (Olympus) at 488 and
633 nm excitations, respectively. For acquisition and image analysis
FluoView (Olympus) software was used.
For efﬂux studies, transfected cells were incubated with 5 μM MX
in the presence of 1 μm Ko143 for 15 min, and washed twice with
medium prior to the experiment. Thereafter the ﬂuorescence was
monitored as described for the drug uptake experiments.
2.2. Analysis of cellular drug uptake
For kinetic analysis, the cells were classiﬁed into two groups (non-
transfected and transfected cells) on the basis of green ﬂuorescence.
To determine the kinetics of intracellular drug accumulation, the
mean far red ﬂuorescence was monitored in various regions of
interest (ROIs) positioned in the cell interior apart from the nuclear
region. The drug extrusion activity of ABCG2 was expressed by theactivity factor calculated from the steady state uptake rates before (Fo)
and after (Fi) Ko143 addition by using the formula (Fi−Fo) /Fi as
described previously [25]. To correlate activity factor with protein
expression at a single cell level, the mean GFP ﬂuorescence was
determined in the plasmamembrane of the individual cells by placing
ROIs over their cell membrane, and the activity factors were plotted
against the corresponding GFP ﬂuorescence values.
To study the kinetics of MX accumulation within the plasma
membrane, the mean far red ﬂuorescence was monitored in ROIs
positioned at the plasma membrane of the cells (cm). The exact
location of the plasma membrane was determined on the basis of GFP
ﬂuorescence. Whenever the plasma membrane changed position, the
ROI was moved accordingly. The proper tracking of the plasma
membrane was veriﬁed by the steady green ﬂuorescence values over
time (see Fig. 3G). In parallel with monitoring GFP and MX
ﬂuorescence in this ROI, the mean far red ﬂuorescence was followed
in another ROI with the exact same shape and size, positioned in the
cell interior adjacent to the ROI at the plasma membrane. The GFP
ﬂuorescence in the second ROI was not different from the background
level. The mean far red ﬂuorescence in this ROI was designated as
internal or submembrane MX ﬂuorescence (ci).
2.3. Transport kinetic models
To describe cellular drug uptake and extrusion, various transport
kinetic models have been generated. In the ﬁrst set of models the
membrane leaﬂets are not distinguished, the plasma membrane is
considered as a “black box.” In these models the drug distribution has
been analyzed in three compartments, i.e., the extracellular space, the
plasma membrane, and the intracellular submembrane region (see
Fig. 4). Model 0 represents the non-transfected (control) cells, in
which no ABCG2 is expressed. Model A corresponds to the ”classical
pump” mechanism, in which the transported substrate is expelled
from cell interior, whereas model B describes a situation, where the
substrate is recognized within the plasma membrane and exported
from this compartment. The latter model includes both the “hydro-
phobic vacuum cleaner” and “ﬂoppase” models. To make our models
manageable, some reasonable assumptions have been introduced. (i)
All transport steps, including ABCG2-mediated transport, are taken as
ﬁrst order kinetic reactions, assuming that the transport capacity of
ABCG2 is much larger than the actual transport rate under the given
conditions (cbKm). (ii) We have considered the external drug
concentration as a constant parameter, based on the fact that the
external volume is orders of magnitude larger than the cell membrane
volume. Thus, in these three-compartment models there are only two
variables: the drug concentration in the membrane (cm) and in the
submembrane region (ci). The differential equations for the three
above mentioned models are as follows.
model 0:
dcm
dt
=
1
Vm
k1ce−k2cm−k−1cm + k−2cið Þ ð1Þ
dci
dt
=
1
Vi
k2cm−k−2cið Þ ð2Þ
model A:
dcm
dt
=
1
Vm
k1ce−k2cm−k−1cm + k−2cið Þ ð3Þ
dci
dt
=
1
Vi
k2cm−k−2ci−k3cið Þ ð4Þ
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dcm
dt
=
1
Vm
k1ce−k2cm−k−1cm−k3cm + k−2cið Þ ð5Þ
dci
dt
=
1
Vi
k2cm−k−2cið Þ ð6Þ
where the designations are as follows: c—concentration, k—rate con-
stant, V—volume; indexes: e—external,m—membrane, i—intracellular
(submembrane).
Although our experimental approach is not suitable for distin-
guishing the individual membrane leaﬂets, to attempt to discriminate
between the “hydrophobic vacuum cleaner” and the “ﬂoppase”
models, we have generated another set of transport kinetic models,
which comprise four compartments (see Fig. 6). In these models, the
plasma membrane is divided into two separate compartments, and
three variables are considered: the drug concentration in the outer
leaﬂet (cm,e), in the inner leaﬂet (cm,i), and in the submembrane
region (ci). There are additional assumptions in these models: (i) the
volumes of the inner and outer leaﬂets are taken as equal; (ii) the rateFig. 1. GFP-tagged ABCG2 prevents cells from intracellular accumulation of ﬂuorescent drug
subjected to mitoxantrone (MX) (A–F) or pheophorbide A (Pheo) (G–L). Confocal images
(pseudo-colored) images depict cellular accumulation of the drugs before (B, E, H, K) and
represent 10 μm. The elapsed times are shown in brackets above the images. Time course
determined and shown by solid lines (tr). Non-transfected cells are represented by dashedconstants for the passive translocation from the outer leaﬂet to the
inner leaﬂet (”ﬂip”) and for the reverse process (”ﬂop”) are
considered as an identical parameter (km). The differential equations
for the four-compartment models are as follows
model 0:
dcme
dt
=
1
Vme
k1ce−kmcme−k−1cme + kmcmið Þ ð7Þ
dcmi
dt
=
1
Vmi
kmcme−kmcmi−k2cmi + k−2cið Þ ð8Þ
dci
dt
=
1
Vi
k2cmi−k−2cið Þ ð9Þ
In model A, the differential equations are the same as in model 0,
with the exception of Eq. (9), which has been modiﬁed as follows:
dci
dt
=
1
Vi
k2cmi−k−2ci−k3cið Þ ð10Þs. HEK-293 cells transfected with GFP-G2 or its inactive mutant variant, GFP-G2KM were
of GFP ﬂuorescence (A, D, G, J) identify transfected cells, whereas far red ﬂuorescence
3 min after the addition of Ko143 (KO), a speciﬁc inhibitor of ABCG2 (C, F, I, L). Bars
of drug uptake in cells transfected with GFP-G2 (M, O) or GFP-G2KM (N, P) were also
lines (non-tr).
Fig. 2. Analysis of mitoxantrone uptake in cells expressing different levels of GFP-G2.
Confocal images of green (A) and far red ﬂuorescence (B) are shown 5 min after MX
addition. Bar represents 10 μm. (C) Kinetic curves of intracellular accumulation of MX
in four selected cells indicated by arrows in the images. The numbers represent the
mean ﬂuorescence intensities of GFP in the plasma membrane. (D) Correlation of the
expression level with the ABCG2-mediated drug extrusion activity factor calculated as
described previously [25].
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the same as it is in model 0:
dcme
dt
=
1
Vme
k1ce−kmcme−k−1cme−k3cme + kmcmiÞð ð11Þ
dcmi
dt
=
1
Vmi
kmcme−kmcmi−k2cmi−k3cmi + k−2cið Þ ð12Þ
Similarly, in model C, Eq. (9) remains the same, but Eqs. (7) and
(8) are modiﬁed as follows:
dcme
dt
=
1
Vme
k1ce−kmcme−k−1cme + kmcmi + k3cmiÞð ð13Þ
dcmi
dt
=
1
Vmi
kmcme−kmcmi−k2cmi−k3cmi + k−2ciÞð ð14Þ
For numerical analysis of the kinetic models, ﬁrst the kinetic
parameters of passive drug uptake were determined in both the
three-compartment or the four-compartment models. Kinetic curves,
based on model 0, were ﬁtted to the pairs of experimental time
courses of cm and ci valuesmeasured in non-transfected (control) cells
using the least squares method. For ﬁtting the four-compartment
model to the experimental values, cm was considered as the mean of
cm,e and cm,i. Once the parameters of passive drug uptake had been
determined, predicted kinetic curves based on either model A, model
B, ormodel Cwere ﬁtted to the pair of experimental time courses of cm
and ci values of GFP-G2-expressing cells, with k3 as a single free
parameter.
3. Results
3.1. Cellular drug uptake in GFP-G2-transfected cells
In our previous work, the applicability of GFP-G2 in ﬂuorescence
transport assay system was demonstrated by using Hoechst 33342,
which becomes ﬂuorescent after interaction with cellular DNA [24].
To study the transport mechanism of the ABCG2 multidrug trans-
porter, we chose such known ABCG2 substrates for the transport
assay, which gain ﬂuorescence in the lipid environment. The uptake of
mitoxantrone (MX) and pheophorbide A (Pheo) were measured in
GFP-G2-expressing HEK-293 cells by confocal microscopy, 48 h after
transfection (Fig. 1). Transfected and non-transfected cells were
identiﬁed on the basis of GFP ﬂuorescence, whereas cellular drug
uptake was monitored by far red ﬂuorescence. As documented in
Fig. 1B, intracellular accumulation of MXwas completely prevented in
GFP-G2-expressing cells, while rapid drug uptake was observed in
non-transfected cells. The addition of Ko143, a speciﬁc inhibitor of
ABCG2 [26], resulted in a fast accumulation of MX even in the GFP-G2-
transfectants without affecting drug uptake in the non-transfected
cells (Fig. 1C), demonstrating that the protection from drug uptake is
due to the transport activity of GFP-G2. The speciﬁcity of drug
extrusion was further supported by the observation that a catalytic
site mutant variant of GFP-G2 (GFP-G2K86M) did not prevent MX
uptake (Fig. 1D–F). Accordingly, for this construct Ko143 addition had
no effect on intracellular drug uptake in either transfected or non-
transfected cells. Similar results were obtainedwhen Pheo uptakewas
measured in GFP-G2- and GFP-G2KM-transfected cells (Fig. 1G–L). The
kinetic curves of intracellular drug accumulation were also obtained
from the image sequences (Fig. 1M–P). Activity factors were
calculated from the drug uptake rates before (Fo) and after (Fi)
inhibitor addition by the formula (Fi−Fo)/Fi as described previously
[25]. In GFP-G2-expressing cells these activity factors were 0.89 and
0.86 for MX and Pheo, respectively, whereas these values were 0 for
both dyes in either non-transfected or GFP-G2KM-expressing cells.24 h after transfection, the expression levels vary from cell to cell.
When dye uptake kinetics and activity factors were determined in
individual cells with different expression levels of GFP-G2 (Fig. 2A–C),
a close correlation between the activity factor and plasma membrane
GFP-ﬂuorescence was found (Fig. 2D). The characteristics of this
relationship are similar to those reported previously for MDR1-
expressing cells [25].3.2. Determination of drug uptake kinetics in the plasma membrane
As mentioned above, in contrast to Hoechst 33342, MX and Pheo
become ﬂuorescent in non-polar environment [27,28]. We observed
that some accumulation of MX also takes place in the plasma
membrane of GFP-G2-expressing cells (Fig. 3D–E), whereas drug
uptake into the internal membranes can be seen only after the
inhibition of the transporter (Fig. 3F). Tracking the position of the
plasma membrane in the GFP image allows determining the kinetics
of MX accumulation separately in the plasma membrane and in the
submembrane regions (Fig. 3G). Drug concentration in the plasma
membrane rapidly saturates in GFP-G2-expressing cells, whereas in
non-transfected cells it shows a continuous increase within the
studied time frame (Fig. 3H). Uptake into the internal membranes
monotonically increased in both cell types, although the uptake rate
was much higher in control cells than in transfectants. GFP-G2KM-
expressing cells exhibited drug accumulation kinetics similar to that
seen in control cells (Fig. 3I), demonstrating that the observed
Fig. 3. Quantitative determination of mitoxantrone accumulation in the plasma membrane. (A–F) Image sequence of a representative mitoxantrone uptake experiment performed
with GFP-G2-transfected HEK-293 cells (for details see the legend of Fig. 1). (A–C) GFP ﬂuorescence; (D–F) far red ﬂuorescence; numbers on the top indicate the elapsed time in
seconds; bars represent 5 μm. The ABCG2 inhibitor KO was added at around 300 s. (G) Kinetic analysis of mitoxantrone uptake experiment shown in Panels A–F. The plasma
membrane was tracked by a region of interest (ROI) on the basis of GFP ﬂuorescence (GFP, triangles). MX accumulation into the plasma membrane was determined by using the
same ROI in the far red ﬂuorescence images (MXmem, squares) while the submembrane dye concentration was measured by another ROI situated next to the ﬁrst one, inside the cell
(MXintra, circles). (H, I) Comparison of mitoxantrone uptake into the plasma membrane (mem, squares) and the submembrane region (intra, circles) of GFP-G2- and GFP-G2KM-
transfected cells (tr, ﬁlled symbols) to that of non-transfected (non-tr, empty symbols) cells. Values are means±S.E.M. of at least four independent experiments.
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expressing cells is due to the activity of the transporter. This notion is
further supported by the observation that addition of Ko143 to GFP-
G2-expressing cells resulted in rapid and continuous elevation in the
plasma membrane drug concentration (Fig. 3G).
3.3. Transport kinetic models of cellular drug uptake
To evaluate the kinetics of drug accumulation in the plasma
membrane and the internal membranes, we generated various
transport kinetic models, which describe cellular drug uptake and
extrusion. Since the experimentally measured parameter is the integral
average of MX ﬂuorescence across the entire plasma membrane, as a
ﬁrst approach a three-compartment model was used, in which the
plasma membrane was considered as a “black box”, the membrane
leaﬂets are not distinguished. Using the three-compartment scheme,
three different models were generated: model 0 describes the drug
movement in the non-transfected (control) cells, whereas model A and
model B illustrate the situationwith theGFP-G2-transfected cells.Model
A corresponds to the “classical pump” mechanism, in which the
transported substrate is expelled from cell interior. In model B the
substrate is recognized within the plasma membrane, thus, this model
combines the “hydrophobic vacuum cleaner” and the “ﬂoppase”models
(see Fig. 4A–C).
These three-compartment models implicitly suggest that the
passive transition rate between the membrane leaﬂets is not a rate
limiting step, thus, it is larger than the diffusion rates to any othercompartments. This assumption is reasonable, considering the
chemical properties of mitoxantrone at pH 7.4, the pH value of the
experiments. This drug is a very weak base, has four amines with two
different dissociation constants (pKa 5.99 and 8.13 in pairs), thus, it is
slightly positively charged at physiological pH. Mitoxantrone is a
hydrophobic molecule, sparingly soluble in water even in its
hydrochloride form [29]. It is more soluble in octanol, but its solubility
is extremely good in lipids as demonstrated in Ref. [30]. The lipid/
water partitioning coefﬁcient for mitoxantrone was found to be
230,000. Taking together these characteristics of mitoxantrone, it is
reasonable to assume that it crosses the plasma membrane at a high
rate. This notion is in accordance with our experimental observation
that MX rapidly accumulates within the non-transfected cells.
To describe our models mathematically, we employed some other
assumptions. The transport activity of ABCG2 was described with a
ﬁrst order kinetics, on the basis of the fact that the transport capacity
substantially exceeds the particular transport rate under the given
conditions (cbKm). Similarly, we assumed that the external drug
concentration (ce) is constant. Although the lipid/water partitioning
coefﬁcient for mitoxantrone is relatively high (230,000) [30] as
mentioned earlier, the several orders of magnitude difference
between the volume of the external space and the cell membranes
along with the short time frame of the study makes this assumption
reasonable. The differential equations for the three different models
are given in Section 2.3 (Eqs. (1)–(6)).
For closed-form solution of the differential equations, we also
assumed that the rate constants for spontaneous drug equilibration
Fig. 4. Kinetic models describing drug uptake and extrusion by a multidrug transporter. (A) Drug uptake into non-transfected, control cells (model 0); (B) Classical
pump mechanism, where the substrate transported from the cytosole (model A); (C) an alternative model, in which the transporter expels its substrate directly from the
membrane (model B). The variables are as follows: c—concentration, k—rate constant, V—volume; indexes: e—external,m—membrane, i—intracellular. The differential equations for
thesemodels are given in Section 2.3 (Eqs. (1)–(6)). (D–E) Closed-form solutions of the kinetic models. Dashed lines: non-transfected cells (non-tr), solid lines: transfected cells (tr);
thick lines: plasma membrane concentrations (mem); thin lines: intracellular concentrations (intra). At the time point 300 s k3 is made equal to 0, mimicking the addition of the
inhibitor.
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are identical both ways (k2=k−2), based on the consideration that
the measured intracellular drug concentration (ci) reﬂects the
mitoxantrone level in internal membranes, thus, in another lipid
environment.
Parametric solution of the differential equations elucidated various
qualitative distinguishing features of the different models. (i) In
model A, the plasma membrane concentration of the drug (cm) in
transfectants differs only slightly from the cm value in control cells,
whereas in model B, cm rapidly saturates at a greatly reduced level
(Fig. 4E–F). (ii) It is also easy to show that the equilibrium values for
cm and ci are different in model A, whereas they approach the same
equilibrium value in model B. For mathematical veriﬁcation see
Statement 1 in the Appendix. iii) Upon addition of an inhibitor to the
system, i.e., when k3 is suddenly made 0, model A predicts a prompt
increase in ci, followed with a delay by an elevation in cm. In contrast,
in model B cm elevates ﬁrst and ci lags behind. In other words, if
an inhibitor is added when the system has already reached
equilibrium, then model A predicts a positive value for the initial
slope of ci and a zero value for that of cm, whereas for model B the
initial slope of cm is positive and that of ci is zero. The detailed
mathematical demonstrations of this statement (Statement 2) can be
found in the Appendix.
3.4. Comparison of experimental data with the kinetic models
The experimental time courses shown in Fig. 5A are congruent
with the features of model B, i.e. (i) cm in transfected cells rapidly
saturates, (ii) cm and ci seem to tend towards the same equilibrium
(see below), and (iii) cm promptly increases after the addition of the
inhibitor (Fig. 5A). To study the equilibrium of cm and ci values further,
we performed an extended uptake experiment without adding
inhibitor to the cells. This experiment also conﬁrmed the validity of
model B, since cm and ci approach the same equilibrium value
(Fig. 5B).To determine the kinetic parameters of passive drug uptake
(k1, k−1, k2, k−2) in our system, we ﬁtted kinetic curves based on
model 0 to the pairs of experimental cm and ci time courses of non-
transfected cells, using the least squares method (Fig. 5A, dashed
lines, RMSE=75.3). Interestingly, the ﬁtting returned k2 equal to k−2,
as was previously assumed based on theoretical considerations for
obtaining closed-form solutions (see above). Using these parameters
we then ﬁtted kinetic curves, based on either model A or model B, to
the pairs of experimental cm and ci time courses of transfected cells,
with k3 as the single free parameter. While the ﬁt was unacceptable
when model A was used (RMSE=655.7, not shown), we obtained a
reasonable ﬁt using model B (Fig. 5A, solid lines, RMSE=158.7). It is
noteworthy that the obtained value for k3 was 108-fold larger than k2
or k−2 when model A was ﬁtted, whereas this ratio proved to be only
35 when model B was used. In other words, overcoming drug inﬂux
would require extremely high transport rates if the drug were
extruded from the cytoplasm, whereas a reasonable transport rate can
efﬁciently compensate for the inﬂux if the drug is expelled directly
from the membrane.
3.5. Kinetics of drug efﬂux and equilibrium drug concentrations
In addition to drug uptake, we also studied efﬂux of mitoxantrone
from preloaded cells. It is easily conceivable that the drug concentra-
tion should decrease ﬁrst in the intracellular compartment, and its
plasma membrane concentration should fall with a delay, if the drug
were extruded from the cell's interior (model A). However, the efﬂux
experiment shown in Fig. 5C demonstrates the reverse situation, i.e.
the drug concentration drops ﬁrst in the membrane followed with a
delay by a decrease in ci,—a scenario which is in accordance with
model B.
Finally, we determined the equilibrium concentrations of mitox-
antrone in the plasma membrane (cm,eq) in cells expressing different
amounts of GFP-G2 as demonstrated in Fig. 5D–E. The inverses of
these values were correlated with GFP-ﬂuorescence, which is
Fig. 5. Experimental evaluations of model predictions on cellular drug accumulation. (A) Experimental values of mitoxantrone uptake into the plasma membrane (mem, squares)
and the submembrane region (intra, circles) of GFP-G2-transfected (tr, ﬁlled symbols) and non-transfected cells (non-tr, empty symbols). Values are means of at least four
independent experiments, error bars are not shown to avoid confusion. Dashed lines represent ﬁtted kinetic curves based on model 0 to the pairs of experimental cm and ci time
courses of non-transfected cells. Similar ﬁtted curves based on model B to the experimental values of GFP-G2-expressing cells are shown by solid lines. Thick lines: plasma
membrane concentrations; thin lines: intracellular concentrations. (B) Determination of equilibrium values of mitoxantrone uptake in GFP-G2-transfected cells. Kinetics of drug
uptake into the plasma membrane (trmem, squares) and the intracellular space (trintra, circles) are shown in a representative extended experiment. Symbols: squares—plasma
membrane; circles—intracellular concentrations. (C) Time course of drug efﬂux from cells preloaded with mitoxantrone. Symbols are the same as in Panel B. (D) Representative
experiment demonstrating mitoxantrone uptake in cells expressing various levels of GFP-G2. (E) Kinetics of mitoxantrone uptake into the plasma membrane of the cells shown in
Panel D. (F) Correlation of the inverses of the equilibrium concentrations of mitoxantrone in the plasma membrane (1/cm,eq) in different GFP-G2-expressing cells with the
corresponding GFP ﬂuorescence. Each symbol represents a value pair (1/cm,eq–GFP ﬂuorescence) for an individual cell; data derived from four independent experiments. Inset shows
model predictions: dependency of 1/cm,eq value on k3 is indicated for both model A and B (for detailed mathematical explanation see Statement 3 in the Appendix).
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constant k3. Model A suggests a saturating curve when 1/cm,eq is
plotted against k3, whereas model B predicts a linear relationship
(inset in Fig. 5F) (for explanation see Statement 3 in the Appendix).
The experimental values exhibit a linear correlation between 1/cm,eq
and GFP ﬂuorescence, providing further support for the validity of
model B (Fig. 5F).
3.6. Four-compartment kinetic models
As discussed above, the three-compartment models imply that the
passive transition across the membrane is not a rate limiting step.
Although this assumption seemed reasonable on the basis of the
chemical properties of mitoxantrone, we considered the possibility
that the membrane translocation rate is comparable with the rates of
the other steps, and generated another set of models, in which the
membrane leaﬂets were considered as separate compartments
(Fig. 6A–D). Similar to the designation used earlier, model 0 describes
the drug movement in the control cells; model A illustrates the
“classical pump” mechanism. Nevertheless, this four-compartment
model scheme allowed us to distinguish between the “hydrophobic
vacuumcleaner” (model B) and the “ﬂoppase”mechanisms (model C).
To keep the number of parameters at a reasonable level, equal volumes
for the inner and outer leaﬂets were assumed, as well as the rate
constants for passive inward and outward translocation in the
membrane were described with a single parameter (km). The
differential equations for the four-compartment models are given in
Section 2.3 (Eqs. (7)–(14)).
Due to resolution limits, our experimental approach does not allow
discriminating between the individual membrane leaﬂets. Therefore,
only two experimental parameters were measured: the mean MX
ﬂuorescence across the entire plasma membrane (cm) and in thesubmembrane region (ci). When ﬁtting the four-compartment
models, this measured cm value was compared with the arithmetic
mean of the predicted cm,i and cm,e values. Similar to the method used
for the three-compartment models, ﬁrst the kinetic parameters of
passive drug uptake (k1, k−1, k2, k−2, km) were determined by ﬁtting
the four-compartment model 0 to the pair of the kinetic curves (cm
and ci) measured in the non-transfected cells (Fig. 6A). This resulted
in a reasonable ﬁt (RMSE=75.7, Fig. 6E), and again returned k2 equal
to k−2. In addition, the membrane translocation rate (km) was
obtained to be 16-fold larger than k−1 and 60-fold larger than k2 or
k−2, supporting our previous assumption that the passive transition
across the membrane is not a rate limiting step.
Using the parameters obtained for the control cells and model 0,
the experimental cm and ci time courses of GFP-G2-expressing cells
were ﬁtted either with model A, model B, or model C, with k3 as a
single free parameter (Fig. 6F–H). Similar to that seen in the case of
the three-compartmentmodels, the ﬁt was unacceptable whenmodel
A was used (Fig. 6F, RMSE=652.1). A substantially better ﬁt was
obtained on the basis of model B (Fig. 6G, RMSE=155.2), neverthe-
less, the best ﬁt was obtained when model C, corresponding to the
“ﬂoppase” mechanism, was used (Fig. 6H, RMSE=38.1).
In addition to separately ﬁtting the time courses of control and
GFP-G2-expressing cells, we also performed ensemble ﬁts of all 8 free
parameters to all four kinetic curves using either model A, model B, or
model C. A reasonable ﬁt was obtained only when model C was used
(RMSE=63.4), returning the same kinetic parameters obtained by
the separate ﬁtting approach. In contrast, 8-parametric ﬁtting with
models A and B resulted in unacceptable ﬁts and meaningless
parameters, e.g., negative rate constants.
In the four-compartment models, we assumed that the passive
“ﬂip” and “ﬂop” rate constants are identical (km). To examinewhether
this assumption is acceptable, we also analyzed a model in which
Fig. 6. Numerical analysis of kinetic models comprising four compartments. In these model schemes the membrane leaﬂets are considered as separate compartments. (A) Model 0
describes drug distribution in non-transfected (control cells); (B–D) drug movement in GFP-G2-espressing cells is shown in accordance with different transport models: the
“classical pump” (model A), the “hydrophobic vacuum cleaner” (model B) and the “ﬂoppase” (model C)mechanisms. Designations are similar used in Fig. 4: c—concentration, k—rate
constant, V—volume; indexes: e—external,m—membrane, i—intracellular;m,i—innermembrane leaﬂet;m,e—outer membrane leaﬂet. The differential equations for these models are
given in Section 2.3 (Eqs. (7)–(14)). (E–H) The four-compartment models were ﬁtted to the experimental time courses of mitoxantrone uptake into the plasma membrane (mem,
squares) and the submembrane region (intra, circles). The solid lines represent the ﬁtted kinetic curves tomembraneMX ﬂuorescence time course, whereas the dashed lines indicate
the intracellular (submembrane) values. The ﬁttings were based on the corresponding models shown above. The experimental values of control cells were ﬁtted with 7 free
parameter using model 0. These parameters were then used for ﬁtting the other models to the time courses of GFP-G2-expressing cells, with k3 as a single free parameter. The quality
of the ﬁts is represented by the root mean square error (RMSE) values. Arrows mark the addition of the drug.
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Interestingly, the ﬁt using this model scheme returned a km,i/km,e ratio
close to 1, verifying the applicability of our original assumption.
Finally, we also examined a modiﬁed model B. In our “hydrophobic
vacuum cleaner” model, drug extrusion was allowed from both
leaﬂets (see Fig. 6C). We analyzed a model scheme in which the
transported substrate is exported exclusively from the inner leaﬂet.
This modiﬁcation of model B had little effect on the ﬁt (data not
shown, RMSE=152.1).
Taken together, the four compartment models provide further
support to the notion that the drug is transported by ABCG2 from the
plasma membrane, rather than from the cell interior. Moreover, this
approach prefers the “ﬂoppase” mechanisms over the “hydrophobic
vacuum cleaner” model.
4. Discussion
To investigate the substrate-transporter interaction, we employed
the fully functional ﬂuorescently labeled multidrug transporter, GFP-
tagged ABCG2 [24] in an on-line confocal microscopic assay system.
The GFP-tag allowed us to identify the ABCG2-expressing cells and to
track down the position of the plasma membrane in living cells. We
studied the cellular uptake of well-known ﬂuorescent substrates of
ABCG2, mitoxantrone and pheophorbide A. The peculiarity of this
experimental setup is that these compounds become ﬂuorescent in
the lipid environment, which feature made possible to determine thedrug concentration in the plasma membrane. We performed a
detailed kinetic analysis of drug uptake and efﬂux, and found that
(i) the plasmamembrane drug concentration (cm) rapidly saturates in
the AGCG2-expressing cells as compared to control cells; (ii) the
plasma membrane and intracellular drug concentrations approach to
the same equilibrium value (cm,eq=ci,eq); (iii) the drug concentration
increases ﬁrst in the plasma membrane, when ABCG2 is inhibited;
(iv) the drug concentration drops ﬁrst in the plasmamembrane in the
efﬂux experiment; (v) there is a linear relationship between 1/cm,eq
values and GFP ﬂuorescence. Numerical analysis of both the three-
compartment and four-compartment models resulted in reasonable
ﬁts only when transport from plasma membrane was assumed
(model B and model C). Acceptable ﬁt was never obtained with
model A.
Taken together, all observed characteristics of mitoxantrone
uptake and efﬂux experiments in concert disprove model A, which
corresponds to the “classical pump” mechanism. Classical pumps
translocate the transported substrate from the cytosole to the external
space through a pore. In contrast, in the “hydrophobic vacuum
cleaner” model, drugs partition into the membrane and are expelled
by the transporter directly from the lipid bilayer. In the “ﬂoppase
model”, drugs are translocated by the transporter from the cytoplas-
mic leaﬂet to the external leaﬂet of the lipid bilayer. This redistribu-
tion of the drug along with the portioning between the membrane
leaﬂets and the aqueous phases results in a net ﬂux of the drug. Both
the hydrophobic vacuum cleaner and ﬂoppase models suggest
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model B, considering the membrane as a “black box”, also based on
substrate recognition within the membrane, and combines these two
mechanisms. The four compartment model scheme, however, where
the membrane leaﬂets are distinguished, may allow discriminating
between the “hydrophobic vacuum cleaner” and the “ﬂoppase”
models. Numerical analysis of these models showed a slight
preference for the “ﬂoppase” mechanism, although we do not feel
conﬁdent to exclude the “hydrophobic vacuum cleaner”model on the
basis of our results. Nevertheless, all approaches clearly invalidated
the “classical pump” mechanism.
Asmentioned earlier, ci is in fact not the cytoplasmic concentration
of MX, but reﬂects the drug level in the internal membranes adjacent
to the plasma membrane. Thus, disapproval of model A at ﬁrst
excludes only the mechanism that the drug is expelled directly from
the internal membrane. Nevertheless, if we assume drug extrusion
from an aqueous layer (quasi cytoplasm) located between the plasma
membrane and the internal membrane compartments, at least a
mixed behavior should be observed, since the drug diffuses equally to
both neighboring compartments. It is easy to see, for instance, that
there would always be a difference in the equilibrium cm and ci values
(cm,eq, ci,eq), or that cm and ci would decrease with the same delay in
the efﬂux experiment, or that there would be no linear relationship
between 1/cm,eq and the expression level, if the changes in the
membrane drug concentrations are indirect consequence of drug
extrusion from the “cytoplasmic” compartment and redistribution of
drug by passive diffusion. Since all the arguments, listed here and
above, unambiguously support the validity of model B in the three-
compartment model, we can excluded drug extrusion from the
aqueous phase.
Some ABC transporters, e.g. MRP1, are known to transport their
substrates by multiple transport mechanisms [4]. Thus, it is plausible
to raise the question whether ABCG2 might extrude drugs from both
the cytoplasm and the plasma membrane. Our observations exclude
the possibility of such a mixed transport mechanism, since cm and ci
approach the same equilibrium (Fig. 5B), and 1/cm,eq exhibited clear
linear relationship with k3 (Fig. 5F). However, it should be mentioned
that our studies were limited to the transport mechanism of one
particular drug, mitoxantrone. It is still possible that other, less
hydrophobic substrates of ABCG2 are transported via the classical
mechanism. It is especially plausible to assume this for water soluble
ABCG2 substrates, such as topotecan, although most ABCG2 sub-
strates, such as ﬂavopiridol, methotrexate, Imatinib mesylate, or
pheophorbide A are strongly hydrophobic.
5. Conclusions
Our study clearly indicates that the anti-cancer drug, mitoxantrone
is expelled by ABCG2 directly from the plasma membrane, providing
unambiguous experimental evidence for the non-canonical way of
action of a multidrug protein. In general, this mechanism can
explain the extremely broad substrate recognition of the multidrug
transporters, which feature is indispensable for fulﬁlling their special
physiological role. In addition, our novel experimental approach,
using substrate molecules, which are ﬂuorescent in the lipid
environment, combined with transport kinetic analysis, offers a new
tool for studying the mechanism of membrane transporters.
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For comparison of the kinetic models with experimental data,
various features of the models were used. These features, given as
statements, can be mathematically veriﬁed as follows.
Statement 1: the equilibrium values for cm and ci are different in
model A, whereas they approach the same equilibrium value in
model B. In equilibrium dci/dt is equal to 0, the relation between the
equilibrium values of cm and ci can be expressed from Eqs. (4) and (6)
as follows
model A:
cm;eq =
k−2 + k3
k2
ci;eq ðA:1Þ
model B:
cm;eq =
k−2
k2
ci;eq ðA:2Þ
With the assumption that k2= k−2 (for explanation see
Section 3.3),
model A:
cm;eq = 1 +
k3
k2
 
ci;eq ðA:3Þ
model B:
cm;eq = ci;eq ðA:4Þ
Since k3 and k2 are positive values, cm,eq is always greater than ci,eq
in model A, whereas they are equal in model B.
Statement 2: if an inhibitor is added when the system has already
reached equilibrium, then model A predicts a positive value for the
initial slope of ci and a zero value for that of cm, whereas for model B
the initial slope of cm is positive and that of ci is zero. To prove this
statement Eqs. (3)–(6) were made equal to zero, and the equilibrium
values of cm and ci were expressed as follows
model A:
cm;eq =
k1 k−2 + k3ð Þ
k2k3 + k−1 k−2 + k3ð Þ
ce ðA:5Þ
ci;eq =
k1k2
k2k3 + k−1 k−2 + k3ð Þ
ce ðA:6Þ
model B:
cm;eq =
k1
k−1 + k3
ce ðA:7Þ
ci;eq =
k1k2
k−2 k−1 + k3ð Þ
ce ðA:8Þ
Eqs. (A.5) and (A.6) were introduced into Eq. (1) or Eq. (2),
mimicking complete inhibition by the inhibitor by model 0
model A:
dcm
dt
= 0 ðA:9Þ
dci
dt
=
k3ci;eq
Vi
ðA:10Þ
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positive values. Similarly, introducing Eqs. (A.7) and (A.8) into Eq. (1)
or Eq. (2) yields
model B:
dcm
dt
=
k3cm;eq
Vm
ðA:11Þ
dci
dt
= 0 ðA:12Þ
The former is always greater then zero, since k3, cm,eq and Vm are
positive values.
Statement 3: model A suggests a saturating curve when 1/cm,eq is
plotted against k3, whereas model B predicts a linear relationship.
Rearrangement of Eqs. (A.5) and (A.7) yields
model A:
1
cm;eq
=
k−1
k1ce
+
1
k1ce
⋅ k2k3
k−2 + k3
ðA:13Þ
model B:
1
cm;eq
=
k−1
k1ce
+
k3
k1ce
ðA:14Þ
Since the volume of the external space is several orders of
magnitude larger than that of the cells, ce is considered as constant,
thus, Eq. (A.14) shows linear relationship between 1/cm,eq and k3. In
contrast, on the basis of Eq. (A.13), 1/cm,eq approaches (k−1+k2)/
(k1ce) as k3 becomes extremely large.
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